Amwill Health Care IPO Subscribed overall 5.73 times on the last day, a retail quota was subscribed over 4.77 times, NII was subscribed over 5.66 times, and QIB was 7.8 respectively.
Details About Amwill Health Care IPO
Amwill Health Care got approval from SEBI for an IPO of around ₹59.98 crores. This IPO comprises a mixture of both fresh issues of ₹48.88 crores and an Offer-for-Sale component of up to 10,00,000 equity shares with a face value of Rs 10 each. Further, it had a set price band between ₹105 to ₹111 Per Share.
In this IPO 1200 shares were in 1 lot size for retail minimum and maximum category as well. Moreover, 2,400 shares were in 2 lot sizes for the S-HNI category.
To invest in this IPO, each investor category has specific investment amounts:
- Retail Investors: Minimum and maximum investment of ₹1,33,200.
- SHNI (S-HNI): Minimum investment of ₹2,66,400.
Amwill Health Care IPO’s Subscription Duration
Amwill Health Care IPO was started on February 5, 2025, and closed on February 7, 2025. The Amwill Health Care IPO’s allotment date was February 10, 2025, and they received a refund on February 11, 2025. While the listing of this IPO was scheduled for February 12, 2025.
Funds Deployment of This IPO
- The raised amount will be used to finalize the determination of the Offer Price and updated in the Prospectus before filing with the ROC
- While the remaining funds will utilized for general corporate purposes and shall not exceed 25% of the Gross Proceeds of the Offer.
About Amwill Health Care Company
Founded in 2009, Amwill Healthcare is one of the leading companies in the business of derma-cosmetics development engaged with contract manufacturers, distributors, and third-party product development agencies. The company mainly focuses on producing dermatological, cosmeceutical, and aesthetical products that suit each and every skin type. For effective management and execution, they outsourced key functions such as manufacturing, prototype development, and distribution to third parties. They aim to become a one-stop solution by providing high-quality ingredients and purity in their skincare products. Proputor Tabs, XL Hydra Cream, Ozederm Cream, PD-Pill 10 Tablets, XL Aqua Moisturizing Lotion, Ultra Kromaglo Effervescent Tablets, and Depimed Ultra Cream are some of the newly added products in their collection. Currently, they have established a business presence in various regions such as Karnataka, Andhra Pradesh, and Telangana.
Financial Resort of the Amwill Health Care Company
The company reported revenue of ₹44.28 crores in 2024 against ₹30.28 a crore in 2023. The company reported a profit of ₹12.54 crores in 2024 against a profit of ₹3.11 crores in 2023.
